Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             56 results found
no title author magazine year volume issue page(s) type
1 Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial Henderson, Michael A
 2015
 16 9 p. 1049-1060
12 p.
 article
2 Adjuvant radiation for patients with melanoma Brady, Mary S
 2015
 16 9 p. 1003-1004
2 p.
 article
3 A novel clinicogenetic prognostic score for follicular lymphoma López-Guillermo, Armando
 2015
 16 9 p. 1011-1012
2 p.
 article
4 Bevacizumab: no comeback in early breast cancer? Bartsch, Rupert
 2015
 16 9 p. 1001-1003
3 p.
 article
5 Cancer risk in the transgender community The Lancet Oncology,
 2015
 16 9 p. 999-
1 p.
 article
6 Cancer strategy to help NHS achieve world-class outcomes Tanday, Sanjay
 2015
 16 9 p. e428-
1 p.
 article
7 Clinical cancer genomic analysis: data engineering required Doig, Kenneth
 2015
 16 9 p. 1015-1017
3 p.
 article
8 Consensus on biomarkers for neuroendocrine tumour disease Oberg, Kjell
 2015
 16 9 p. e435-e446
nvt p.
 article
9 Consensus on the management of intracranial germ-cell tumours Murray, Matthew J
 2015
 16 9 p. e470-e477
nvt p.
 article
10 Correction to Lancet Oncol 2011; 12: 1051 2015
 16 9 p. e427-
1 p.
 article
11 Correction to Lancet Oncol 2015; 16: 1127 2015
 16 9 p. e427-
1 p.
 article
12 Correction to Lancet Oncol 2015; 16: 634, 637 2015
 16 9 p. e427-
1 p.
 article
13 Correction to Lancet Oncol 2015; 16: 388 2015
 16 9 p. e427-
1 p.
 article
14 Correction to Lancet Oncol 2015; 16: 967–78 2015
 16 9 p. e427-
1 p.
 article
15 Disparities in cancer mortality for elderly poor in the USA Gruber, Karl
 2015
 16 9 p. e431-
1 p.
 article
16 Docetaxel for hormone-sensitive metastatic prostate cancer Baker, Holly
 2015
 16 9 p. e432-
1 p.
 article
17 Edinburgh Festival Fringe Round Up Murray, Andrew Hunter
 2015
 16 9 p. 1021-1022
2 p.
 article
18 Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial Moss, Sue M
 2015
 16 9 p. 1123-1132
10 p.
 article
19 EMA paediatric medicine waivers Burki, Talha Khan
 2015
 16 9 p. e429-
1 p.
 article
20 Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies 2015
 16 9 p. 1061-1070
10 p.
 article
21 Epigenetic approaches to overcoming chemotherapy resistance Strauss, Julius
 2015
 16 9 p. 1013-1015
3 p.
 article
22 Faces of breast cancer: a personal approach Lobo, Patricia
 2015
 16 9 p. 1024-
1 p.
 article
23 Fewer than three doses of HPV vaccine Lehtinen, Matti
 2015
 16 9 p. e422-e423
nvt p.
 article
24 Fewer than three doses of HPV vaccine Jit, Mark
 2015
 16 9 p. e423-e424
nvt p.
 article
25 Fewer than three doses of HPV vaccine – Authors' reply Kreimer, Aimée R
 2015
 16 9 p. e424-e425
nvt p.
 article
26 Genetic mutations and outcome in myeloma Bagcchi, Sanjeet
 2015
 16 9 p. e434-
1 p.
 article
27 Genetic testing for patients with colorectal cancer Burki, Talha Khan
 2015
 16 9 p. e430-
1 p.
 article
28 Guadecitabine for AML and MDS: hype or hope? Kharfan-Dabaja, Mohamed A
 2015
 16 9 p. 1009-1011
3 p.
 article
29 High HLA-DP expression and graft-versus-host disease Baker, Holly
 2015
 16 9 p. e434-
1 p.
 article
30 Hypofractionated breast radiation reduces acute toxicities Brower, Vicki
 2015
 16 9 p. e432-
1 p.
 article
31 Ibrutinib promising in subtype of DLBCL Brower, Vicki
 2015
 16 9 p. e428-
1 p.
 article
32 Inherited cylindromas: lessons from a rare tumour Rajan, Neil
 2015
 16 9 p. e460-e469
nvt p.
 article
33 Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry Pastore, Alessandro
 2015
 16 9 p. 1111-1122
12 p.
 article
34 MRS for non-invasive medulloblastoma subgrouping Bagcchi, Sanjeet
 2015
 16 9 p. e433-
1 p.
 article
35 Neoadjuvant chemoradiation in oesophageal cancer Mariette, Christophe
 2015
 16 9 p. 1008-1009
2 p.
 article
36 Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial Shapiro, Joel
 2015
 16 9 p. 1090-1098
9 p.
 article
37 Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial Bear, Harry D
 2015
 16 9 p. 1037-1048
12 p.
 article
38 NICE guidance on nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer Hall, Caroline J
 2015
 16 9 p. 1019-1020
2 p.
 article
39 Nodal radiation in breast cancer does not improve survival Brower, Vicki
 2015
 16 9 p. e430-
1 p.
 article
40 Now and at the Hour of Our Death Burki, Talha Khan
 2015
 16 9 p. 1023-
1 p.
 article
41 Research funding under review in UK and USA Burki, Talha Khan
 2015
 16 9 p. 1018-
1 p.
 article
42 Role of rolapitant in chemotherapy-induced emesis Olver, Ian
 2015
 16 9 p. 1006-1007
2 p.
 article
43 SABR vs surgery for NSCLC in the media Rice, David
 2015
 16 9 p. e422-
1 p.
 article
44 Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study Reid, Tony
 2015
 16 9 p. 1133-1142
10 p.
 article
45 Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials Rapoport, Bernardo L
 2015
 16 9 p. 1079-1089
11 p.
 article
46 Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial Schwartzberg, Lee S
 2015
 16 9 p. 1071-1078
8 p.
 article
47 Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study Issa, Jean-Pierre J
 2015
 16 9 p. 1099-1110
12 p.
 article
48 T-cell receptor therapy shows promise in multiple myeloma Bagcchi, Sanjeet
 2015
 16 9 p. e429-
1 p.
 article
49 The Pill's gestation: from birth control to cancer prevention Wentzensen, Nicolas
 2015
 16 9 p. 1004-1006
3 p.
 article
50 The UK Age Trial: screening women in their forties Kopans, Daniel B
 2015
 16 9 p. 1012-1013
2 p.
 article
51 Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer Tan, Chee-Seng
 2015
 16 9 p. e447-e459
nvt p.
 article
52 Trends in euthanasia and assisted suicide Burki, Talha Khan
 2015
 16 9 p. e433-
1 p.
 article
53 Urine test can detect early stage pancreatic cancer Bagcchi, Sanjeet
 2015
 16 9 p. e431-
1 p.
 article
54 Vosaroxin in acute myeloid leukaemia Bornhäuser, Martin
 2015
 16 9 p. 1000-1001
2 p.
 article
55 Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study Ravandi, Farhad
 2015
 16 9 p. 1025-1036
12 p.
 article
56 Will the revised class waiver list make it? Vassal, Gilles
 2015
 16 9 p. e425-e426
nvt p.
 article
                             56 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands